Academic Journals Database
Disseminating quality controlled scientific knowledge

Targeting Angiogenesis in Non-Small Cell Lung Cancer: Agents in Practice and Clinical Development

ADD TO MY LIST
 
Author(s): Afsaneh Barzi | Nathan A Pennell

Journal: European Journal of Clinical & Medical Oncology
ISSN 1759-8958

Volume: 2;
Issue: 1;
Start page: 31;
Date: 2010;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: vascular endothelial growth factor | tyrosine kinase inhibitors | angiogenesis | clinical trials

ABSTRACT
Molecularly targeted therapies are becoming increasingly important in clinical oncology practice. Several critical molecular pathways have been identified, and novel therapeutic agents targeting these pathways are now approved and administered routinely in different solid malignancies. Angiogenesis, and in particular the vascular endothelial growth factor (VEGF) pathway, plays a central role in the development and progression of solid malignancies including non-small cell lung cancer (NSCLC). Agents designed to target this pathway include both antibodies targeting VEGF and small molecule tyrosine kinase inhibitors that can inhibit signaling through the VEGF receptors. A number of agents targeting the VEGF pathway have shown promising results in the treatment of NSCLC, and some, such as bevacizumab, have even been approved and are available for routine administration in combination with chemotherapy for patients with NSCLC. This is a concise review of the major angiogenic pathways and the targeted agents designed to block these pathways. The review will focus on the benefits of antiangiogenic agents that are in advanced clinical development in NSCLC, as well as the future direction of this field.
RPA Switzerland

Robotic Process Automation Switzerland

    

Tango Jona
Tangokurs Rapperswil-Jona